Advertisement

Topics

Search Results for "Mylan Atovaquone And Proguanil 250mg 100mg Tablet"

09:37 EDT 4th May 2016 | BioPortfolio

Matching Channels

Selective monoamine oxidase type B MAOB inhibitors

The clinical benefit of monoamine oxidase type B (MAO-B) inhibitors is thought to arise from an ability of these medications to enhance the level of dopamine by decreasing the catabolism. Additional...

Matching News

Resistance to antimalarial atovaquone does not spread

Atovaquone could be used more widely to treat malaria since resistance does not spread to subsequent generations of the malaria parasite.

Australian researchers confirm Atovaquone's ability to combat malaria parasite

Researchers at the University of Melbourne, Australia, have discovered that an anti-malarial drug called Atovaquone, which was thought to be ineffective, has the ability to combat the malaria parasite...

Mutant malaria parasites resistant to antimalarial Atovaquone cannot spread: new research

By Prodita Sabarini, The Conversation Resistance to a commonly used antimalarial medication, Atovaquone, can’t spread to the general human population, new research suggests. This is significant as s...

Perrigo rejects $26 billion hostile Mylan takeover bid

Perrigo has rejected Mylan’s hostile $26 billion bid after a 60% majority of shareholders were unconvinced by the terms by the Friday deadline. As the offer has now lapsed, Mylan is unable to bid ag...

Perrigo rejects Mylan acquisition

Shareholders of Perrigo Co. plc (NYSE:PRGO; Tel Aviv:PRGO) rejected a hostile tender offer from Mylan N.V. (NASDAQ:MYL). Perrigo said more than 60% of its shareholders refused Mylan's bid. Mylan had o...

Mylan Allowed to Continue Takeover Bid for Perrigo

A federal district court judge is allowing Mylan to continue its hostile takeover bid for Perrigo. In Perrigo Company PLC v. Mylan NV, Perrigo claimed Mylan made false statements by saying it expect...

Mylan expands biosimilar development in deal with Momenta

Mylan has agreed to pay Momenta $45 million to co-develop and commercialize six biosimilars, adding to Mylan's earlier biosi -More- 

Perrigo shareholders reject Mylan takeover bid

Mylan needed at least 50% of Perrigo's shares tendered to take over the company but received only 40%, Mylan announced. -More- 

Matching PubMed Articles

Exploration of the associations of touch-screen tablet computer usage and musculoskeletal discomfort.

Tablet users may be at high risk of developing physical discomfort because of their usage behaviors and tablet design.

Switching from a two-tablet regimen of tenofovir/emtricitabine and efavirenz to a one-tablet regimen may affect patients' perceptions and drug management.

Simplification of antiretroviral therapy enhances a patient's adherence but a new formulation could also lead to new adverse events and changes in daily routine. This study compared medication adheren...

Synthesis of a novel superdisintegrant by starch derivatization with polysuccinimide and its application for the development of Ondansetron fast dissolving tablet.

Disintegrants are the key excipients administered in tablet formulations to boost the decomposition of the tablet into smaller pieces in the gastrointestinal environment, thereby increasing the availa...

Tablet Apps and Dexterity: Comparison Between 3 Age Groups and Proof of Concept for Stroke Rehabilitation.

Touch screen tablet technology might be suitable for self-training of impaired dexterity poststroke. We compared performance of app-based hand activities in individuals without a disability from 3-age...

Adapting to the surface: A comparison of handwriting measures when writing on a tablet computer and on paper.

Our study addresses the following research questions: Are there differences between handwriting movements on paper and on a tablet computer? Can experienced writers, such as most adults, adapt their g...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement